| Trial ID: | L5364 |
| Source ID: | NCT02536859
|
| Associated Drug: |
Insulin Degludec
|
| Title: |
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: insulin degludec|DRUG: insulin glargine
|
| Outcome Measures: |
Primary: Area under the glucose infusion rate curve, During one dosing interval (0-24h) at steady-state. At day 6, 9 and 12 | Secondary: Area under the glucose infusion rate curve, During one dosing interval at steady state.At day 6, 9 and 12
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-08-31
|
| Completion Date: |
2016-04-14
|
| Results First Posted: |
|
| Last Update Posted: |
2019-05-01
|
| Locations: |
Novo Nordisk Investigational Site, Neuss, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02536859
|
